Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Fractyl Health is a clinical-stage biotechnology company developing Rejuva, a proprietary endoscopic procedure targeting metabolic diseases including type 2 diabetes and obesity. The company's lead technology uses duodenal mucosal resurfacing (DMR) to restore metabolic function by ablating and regenerating intestinal tissue. With no commercial revenue and negative operating cash flow of $100M annually, the stock trades on clinical trial milestones and regulatory pathway progress.
Fractyl is developing a one-time endoscopic procedure (Rejuva) that aims to treat metabolic diseases by resurfacing duodenal mucosa. The business model depends on achieving FDA approval, securing favorable reimbursement codes from CMS and private payers, and demonstrating durable clinical outcomes that justify premium pricing versus existing GLP-1 drugs and bariatric surgery. Revenue would come from procedure fees, device sales to hospitals/ASCs, and potential royalties. The company has no pricing power until clinical efficacy is proven and regulatory approval obtained. Current burn rate of ~$100M annually requires additional capital raises before commercialization.
Rejuva pivotal trial enrollment updates and interim efficacy data (HbA1c reduction, weight loss endpoints)
FDA regulatory interactions - breakthrough device designation status, IDE approval progress, pre-market approval (PMA) pathway clarity
Capital raises and cash runway extensions - dilution events typically pressure stock given negative FCF of $100M
Competitive positioning versus GLP-1 drugs (Ozempic, Mounjaro) and emerging obesity treatments
CMS reimbursement pathway developments for metabolic endoscopic procedures
GLP-1 drug class dominance in obesity/diabetes market - Ozempic, Wegovy, Mounjaro achieving massive adoption with proven efficacy may limit addressable market for procedural alternatives
Reimbursement uncertainty for novel metabolic procedures - CMS and private payers historically conservative on covering experimental endoscopic treatments without long-term durability data
Regulatory pathway complexity - DMR procedure requires PMA approval with extensive safety/efficacy data, creating multi-year timeline and binary approval risk
Established bariatric surgery procedures (gastric bypass, sleeve gastrectomy) with decades of outcomes data and existing reimbursement infrastructure
Next-generation GLP-1 drugs and combination therapies in development offering oral formulations and improved side effect profiles
Other endoscopic metabolic device companies (e.g., intragastric balloons, duodenal sleeves) competing for same patient population and reimbursement dollars
Severe cash burn of $100M annually with no revenue creates existential financing risk - company must access capital markets repeatedly before commercialization
Negative equity position (ROE -3,645%, Price/Book -8.2x) indicates accumulated deficit exceeds assets, limiting borrowing capacity and forcing equity dilution
Stock price decline of 74% over past year significantly impairs ability to raise capital on favorable terms - death spiral risk if forced to issue equity at depressed valuations
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, ability to raise capital in public/private markets is highly sensitive to risk appetite and biotech sector sentiment. Economic downturns reduce investor willingness to fund cash-burning clinical assets.
High sensitivity through multiple channels: (1) Rising rates compress biotech valuations as future cash flows are discounted more heavily - particularly punitive for pre-revenue assets with 5-10 year commercialization timelines. (2) Higher rates increase cost of capital for future financing rounds. (3) Rates affect institutional allocation to speculative growth versus safer fixed income. The 10-year Treasury yield directly impacts discount rates used in DCF models for clinical-stage biotechs.
Moderate - Company depends on access to capital markets (equity and convertible debt) to fund operations until commercialization. Tightening credit conditions and risk-off sentiment in biotech lending markets could impair ability to raise necessary capital, forcing unfavorable dilution or strategic alternatives. Current ratio of 4.27 suggests adequate near-term liquidity, but negative $100M annual cash burn requires ongoing financing access.
growth - Highly speculative clinical-stage biotech attracts venture-style investors willing to accept binary outcomes (FDA approval/rejection) for asymmetric upside potential. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors seeking lottery-ticket exposure. Not suitable for value or income investors given no earnings, no dividends, and negative book value. Requires high risk tolerance and long time horizon.
high - Stock exhibits extreme volatility typical of clinical-stage biotechs with no revenue. 74% decline over past year and 72% drop in 3 months demonstrates sensitivity to trial updates, financing events, and sector sentiment. Beta likely exceeds 2.0 relative to broader market. Single clinical trial readouts can move stock 50%+ in either direction.
